Searchable abstracts of presentations at key conferences in endocrinology

ea0026s10.3 | New developments in the therapy for NETs | ECE2011

New developments in the therapy for NETs: new drugs including mTOR inhibitors

Grozinsky-Glasberg Simona

Mammalian target of rapamycin (mTOR), a main serine/threonine protein kinase in the phosphoinositide 3-kinase (PI3K)/Akt/p70S6K signalling pathway, is an important intracellular mediator involved in multiple cellular functions including proliferation, differentiation, apoptosis, tumorigenesis, angiogenesis, and also longevity.Recent studies indicate that mTOR is central in the integration of a multitude of signalling pathways activated by growth factors ...

ea0081p384 | Endocrine-Related Cancer | ECE2022

Appendiceal neuroendocrine neoplasms diagnosed during pregnancy-case series and review of the literature

Twito Orit , Amit Akirov , Chava Rosenblum Rachel , Herzberg Dana , Oleinikov Kira , Pnina Rotman-Pikielny , Glasberg Simona

Introduction: Although appendicitis occurs in approximately 1:1000 pregnancies, appendiceal neuroendocrine neoplasm (ANEN) diagnosis during pregnancy is very rare. Data on presentation, treatment and prognosis is scarce.Aim: To describe ANEN cases diagnosed during pregnancy.Materials and Methods: A retrospective appraisal of 7 consecutive ANEN patients diagnosed during pregnancy from four Israeli tertiary medical centers and compar...

ea0050p242 | Neoplasia, Cancer and Late Effects | SFEBES2017

Combination of JQ1, an inhibitor of epigenetic pathways, and everolimus for treatment of pancreatic and bronchial neuroendocrine tumours

Lines Kate E , Stevenson Mark , Filippakopoulos Panagis , Grozinsky-Glasberg Simona , Bountra Chas , Thakker Rajesh V

Current treatments, including surgery, medical therapy, radiotherapy, and radionuclide therapy for neuroendocrine tumours of the pancreas (PNETs) and bronchus (BNETs) are often unsatisfactory, leading to a 5-year survival of <50% and 5%, respectively. PNETs and BNETs frequently have mutations in chromatin-remodelling genes and the protein encoded by the multiple endocrine neoplasia type 1 (MEN1) gene, menin. Menin binds the...

ea0050p242 | Neoplasia, Cancer and Late Effects | SFEBES2017

Combination of JQ1, an inhibitor of epigenetic pathways, and everolimus for treatment of pancreatic and bronchial neuroendocrine tumours

Lines Kate E , Stevenson Mark , Filippakopoulos Panagis , Grozinsky-Glasberg Simona , Bountra Chas , Thakker Rajesh V

Current treatments, including surgery, medical therapy, radiotherapy, and radionuclide therapy for neuroendocrine tumours of the pancreas (PNETs) and bronchus (BNETs) are often unsatisfactory, leading to a 5-year survival of <50% and 5%, respectively. PNETs and BNETs frequently have mutations in chromatin-remodelling genes and the protein encoded by the multiple endocrine neoplasia type 1 (MEN1) gene, menin. Menin binds the...

ea0063gp3 | Adrenal and Neuroendocrine - Tumour | ECE2019

ProGRP is an effective marker for disease monitoring in lung carcinoids with non-informative chromogranin A: Lessons from clinical practice

Oleinikov Kira , Grozinsky-Glasberg Simona , Gross David J , Nechushtan Hovav , Peretz Tamar , Maimon Ophra , Nisman Beni

Introduction: The histologic classification of lung carcinoids (LCs) as typical (TCs) and atypical (ACs) highlights its role as major prognostic factor for these patients. However, in the absence of sensitive biomarkers to effectively predict tumor behavior, long-term imaging surveillance is recommended for disease monitoring. Limited data suggest that progastrin-releasing peptide (ProGRP) may have diagnostic & monitoring utility in LCs.Aim(s): To ev...

ea0063p12 | Adrenal and Neuroendocrine Tumours 1 | ECE2019

Combined autophagy and mTOR inhibition reduces cells proliferation and induces apoptosis in a lung carcinoid in-vitro model

Knigin Adi , Avniel-Polak Shani , Gross David J , Grozinsky-Glasberg Simona

Introduction: Treatment options for patients with metastatic lung carcinoids (LC) are limited. Everolimus (RAD001), an mTOR inhibitor (mTORi) which suppresses tumor cells growth & proliferation, appears to be efficient in these patients; however, it promotes autophagy, thereby paradoxically supporting tumor cell survival and development of drug-resistance. We have previously demonstrated in a BON1 pancreatic NEN model that adding chloroquine (CQ, an autophagy inhibitor) to...

ea0049ep1391 | Thyroid (non-cancer) | ECE2017

The impact of age and gender on the presentation and prognosis of medullary thyroid cancer – an Israeli multicenter study

Twito Orit , Grozinsky-Glasberg Simona , Benbassat Carlos , Llevy Sigal , Bachar Gideon , Gross David J , Hirsch Dania

Background: Data regarding the effect of gender and age on medullary thyroid cancer (MTC) presentation and prognosis is limited. Although older age and male sex were found to correlate with poorer prognosis in some studies, this correlation may reflect differences in MTC presentation between sex and age groups, or a mixture of hereditary and sporadic MTC forms.Objective: To evaluate the impact of age and sex on the presentation and outcomes of MTC.<p...

ea0059p117 | Neoplasia, cancer &amp; late effects | SFEBES2018

Epigenetic inhibitor treatment reduces proliferation via induction of apoptosis in a human typical bronchial carcinoid cell line

Selberherr Andreas , Lines Kate E , Gronzinsky-Glasberg Simona , Bountra Chas , Thakker Rajesh V

Neuroendocrine tumours (NETs), occurring at multiple sites including the pancreas, lung and pituitary, are increasing in incidence and usually present at an advanced metastatic stage, and current medical treatments have limited efficacy. Epigenetic modifiers are promising new drugs, as mutations in the multiple endocrine neoplasia type 1 (MEN1) gene, encoding the histone methyltransferase MLL1 interacting protein, menin, are known to cause both familial and sporadic N...

ea0081oc14.6 | Oral Communications 14: Late Breaking | ECE2022

Engaging the Endocannabinoid System in Neuroendocrine Neoplasms (NENs) potentiates treatment outcomes and null drug resistance

Avniel- Polak Shani , Polak David , Oleinikov Kira , Gross David J , Wald Ori , Izhar Uzi , Mazeh Haggi , Drier Yotam , Glasberg Simona

Introduction: Patients with unresectable NENs are offered a variety of non-curable therapeutic options, which eventually fail due to drug resistance. Increasing evidence suggest an anticancer trait of cannabinoids, via cellular pathways including mTOR, known to be associated with drug resistance development. Still, limited data exist on the anti-cancer effects of cannabinoids in NENs.Aims: To understand the possible anti-tumor role of the cannabinoids an...

ea0044p125 | Neoplasia, cancer and late effects | SFEBES2016

Multiple endocrine neoplasia type 1 (MEN1) in identical twins, with different MEN1 tumours, is due to a deletion of the MEN1 5′ untranslated region (UTR)

Kooblall Kreepa , Cranston Treena , Lines Kate , Stevenson Mark , Rogers Angela , Grozinsky-Glasberg Simona , Flanagan Daniel , Thakker Rajesh

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by the occurrence of parathyroid, pancreatic and pituitary tumours, and is due to mutations of the MEN1 gene, which encodes menin. We have investigated identical twins with MEN1, one of whom developed primary hyperparathyroidism (PHPT) and a prolactinoma that caused pubertal arrest, and the other had PHPT only. DNA sequence analysis of the MEN1 coding region had not ide...